ReviewFrontiers in pharmacology2015
Therapeutic strategies for preventing skeletal muscle fibrosis after injury.
Review in Frontiers in pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 82 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
Prospective Cohort Study of Athletes Following an Injection of Platelet-Poor Plasma Into an Acute Muscle Injury
Who cites it
82 citing papers in PubMed, 155 citations in OpenAlex.
- Intensity Dependent Effects of Interval Resistance Training on Myokines and Cardiovascular Risk Factors in Males With Obesity.Frontiers in endocrinology · 2022Trial
- Telocytes in skeletal muscle: Emerging players in homeostasis and repair/regeneration.Histology and histopathology · 2026Review
- Click-crosslinked nanogels integrated into 3D stem cell spheroids enhance regenerative function for swallowing muscle repair.Biomaterials · 2026Article
- ROS-Triggered Microgels for Programmable Drug Release in Volumetric Muscle Loss Repair.Advanced healthcare materials · 2026Article
- Deconstruction of cellular dynamics after treatment of volumetric muscle loss injury with extracellular matrix.NPJ Regenerative medicine · 2025Article
- A sandwich-like nanofibrous scaffold with macrophage phenotype transformation and myogenic differentiation for skeletal muscle regeneration.Bioactive materials · 2025Article
- Editorial on sartans and skeletal muscle regeneration: rethinking fibrosis as a modifiable target in traumatic injury.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2025Article
- Microvascularization of the Vocal Folds: Molecular Architecture, Functional Insights, and Personalized Research Perspectives.Journal of personalized medicine · 2025Review
- Unveiling the Potential of Bioactive Glass in Volumetric Muscle Loss Regeneration.Materials (Basel, Switzerland) · 2025Review
- Preclinical validation of TGFβ inhibitors as a novel therapeutic strategy for post-traumatic heterotopic ossification.Scientific reports · 2025Article
- Effects of injury size on local and systemic immune cell dynamics in volumetric muscle loss.NPJ Regenerative medicine · 2025Article
- Biosponge-Encased Placental Stem Cells for Volumetric Muscle Loss Repair.Advances in wound care · 2025Article
- In Sequence Antifibrotic Treatment and Rehabilitation after Volumetric Muscle Loss Injury.Advances in wound care · 2025Article
- Effects of Aging on Intramuscular Collagen-Related Factors After Injury to Mouse Tibialis Anterior Muscle.International journal of molecular sciences · 2025Article
- Reversing Decline in Aging Muscles: Expected Trends, Impacts and Remedies.Journal of functional morphology and kinesiology · 2025Review
- Adipose-derived stem cells alleviate radiation-induced muscle fibrosis by promoting muscle regeneration.Frontiers in cell and developmental biology · 2025Article
- Targeted Therapy for Skeletal Muscle Fibrosis: Regulation of Myostatin, TGF-β, MMP, and TIMP to Maintain Extracellular Matrix Homeostasis.Biologics : targets & therapy · 2025Review
- Exercise and tissue fibrosis: recent advances in therapeutic potential and molecular mechanisms.Frontiers in endocrinology · 2025Review
- Fibrosis and Sports Injuries: Concept and Implications: The GESMUTE-SETRADE Consensus Statement.Orthopaedic journal of sports medicine · 2024Article
- Effects of injury size on local and systemic immune cell dynamics in volumetric muscle loss.bioRxiv : the preprint server for biology · 2024Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skeletal muscle repair after injury includes a complex and well-coordinated regenerative response. However, fibrosis often manifests, leading to aberrant regeneration and incomplete functional recovery. Research efforts have focused on the use of anti-fibrotic agents aimed at reducing the fibrotic response and improving functional recovery. While there are a number of mediators involved in the development of post-injury fibrosis, TGF-β1 is the primary pro-fibrogenic growth factor and several agents that inactivate TGF-β1 signaling cascade have emerged as promising anti-fibrotic therapies. A number of these agents are FDA approved for other conditions, clearing the way for rapid translation into clinical treatment. In this article, we provide an overview of muscle's host response to injury with special emphasis on the cellular and non-cellular mediators involved in the development of fibrosis. This article also reviews the findings of several pre-clinical studies that have utilized anti-fibrotic agents to improve muscle healing following most common forms of muscle injuries. Although some studies have shown positive results with anti-fibrotic treatment, others have indicated adverse outcomes. Some concerns and questions regarding the clinical potential of these anti-fibrotic agents have also been presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.